US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
Jessica Biel unveiled a dramatic hair transformation - from chest-length locks to a short bob - on S2024-05-21Xi Focus: Key Takeaways from Xi's Meetings with Foreign Guests
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Theatrical play in Athens unveils life after cancer
Video PlayerCloseCancer survivors pose for photos in a theatrical play in Athens, Greece, March 16,2024-05-21- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
French sports minister calls for sanctions after Monaco player tapes over anti
PARIS (AP) — France’s sports minister has called for soccer club Monaco to be sanctioned after one o2024-05-21China unveils plan to promote trade
BEIJING, April 12 (Xinhua) -- China has rolled out specific measures to facilitate and encourage tra2024-05-21
atest comment